房地产/房地产开发 华润置地（01109.HK） 2025 年 03 月 27 日 投资评级：买入（维持） 数据来源：聚源 -40% -20% 0% 20% 40% 60% 2024-03 2024-07 2024-11 华润置地 恒生指数 | 日期 | 2025/3/26 | | --- | --- | | 当前股价(港元) | 25.850 | | 一年最高最低(港元) | 33.700/18.560 | | 总市值(亿港元) | 1,843.35 | | 流通市值(亿港元) | 1,843.35 | | 总股本(亿股) | 71.31 | | 流通港股(亿股) | 71.31 | | 近 3 个月换手率(%) | 15.89 | 股价走势图 相关研究报告 《长风万里稳行舟，多元驱动占鳌头 —港股公司首次覆盖报告》-2025.3.4 结转业绩稳健，经常性利润贡献过百亿 ——港股公司信息更新报告 | 齐东（分析师） | 胡耀文（分析师） | 杜致远（联系人） | | --- | --- | --- | | qidong@kysec.cn | huyaowen@kysec.cn | duzhiyuan@kys ...

公 司 研 究 / 公 司 点 评 食品饮料 2025 年 03 月 27 日 农夫山泉 (09633) 上 市 公 司 ——艰难时点已过 25 年关注瓶装水业务复苏 报告原因：有业绩公布需要点评 | 投资要点： | | --- | 财务数据及盈利预测 | | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 42,667 | 42,896 | 49,355 | 55,402 | 61,534 | | 同比增长率（%） | 28 | 1 | 15 | 12 | 11 | | 归母净利润（百万元） | 12,079 | 12,123 | 13,990 | 15,800 | 17,772 | | 同比增长率（%） | 42 | 0 | 15 | 13 | 12 | | 每股收益（元/股） | 1.07 | 1.08 | 1.24 | 1.40 | 1.58 | | 净资产收益率（%） | 42.28 | 37.55 | 37.08 | 36.13 | 35.23 | | 市盈率 | 2 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The company is expected to achieve a natural gas sales volume of 54.17 billion cubic meters in 2024, representing a year-on-year growth of 9.9%, with retail gas volume increasing by 8.1% [2][6]. - The company’s revenue for 2024 is projected to be 187.046 billion yuan, a year-on-year increase of 5.46%, with net profit attributable to shareholders reaching 5.960 billion yuan, up 4.89% [6]. - The company emphasizes shareholder returns, with a planned annual dividend of 0.3158 yuan per share, resulting in a payout ratio of 43% and a dividend yield of 4.18% based on the closing price on the report date [2][6]. Summary by Sections Sales Performance - The company’s industrial gas volume is expected to account for 74.9% of total sales in 2024, an increase of 5.5 percentage points year-on-year, with industrial gas volume rising by 16.5% [2][6]. - Retail gas volume in the northwest and southwest regions is projected to grow by 12% and 19.2% respectively, significantly outpacing the national average growth rate of 8% [6]. Financial Performance - The company’s LNG processing and storage business revenue is expected to grow by 1.6%, while the tax profit remains stable with a slight increase of 0.2% [6]. - The average load rate of LNG receiving stations is projected to be 87.6%, a decrease of 3 percentage points year-on-year, while LNG processing volume is expected to increase by 25.6% [6]. Dividend Policy - The company has announced a three-year dividend plan aiming for a payout ratio of 45% of net profit by the end of the fiscal year 2025 [6]. - The company has initiated interim dividends for the first time, with a payout of 0.1641 yuan per share for the interim and 0.1517 yuan per share for the final dividend [6].

交银国际研究 公司更新 | 医药 | 收盘价 | | 目标价 | 潜在涨幅 | 2025 年 3 月 27 日 | | --- | --- | --- | --- | --- | --- | | 港元 | | 54.20 | 港元 65.00↑ | +19.9% | | | 云顶新耀 (1952 HK) | | | | | | 2024 年实现商业化层面盈利，耐赋康快速渗透目标市场，上调目标价 | 财务数据一览 | | | | | | | --- | --- | --- | --- | --- | --- | | 年结12月31日 | 2023 | 2024 | 2025E | 2026E | 2027E | | 收入 (百万人民币) | 126 | 707 | 1,689 | 2,819 | 3,908 | | 同比增长 (%) | 884.5 | 461.2 | 138.9 | 66.9 | 38.6 | | 净利润 (百万人民币) | (844) | (1,041) | (264) | 311 | 794 | | 每股盈利 (人民币) | (2.80) | (3.24) | (0.81) | 0.96 ...

交银国际研究 公司更新 | 医药 | 收盘价 | | 目标价 | 潜在涨幅 | 2025 年 3 月 27 日 | | --- | --- | --- | --- | --- | --- | | 港元 | | 54.20 | 港元 65.00↑ | +19.9% | | | 云顶新耀 (1952 HK) | | | | | | 2024 年实现商业化层面盈利，耐赋康快速渗透目标市场，上调目标价 | 财务数据一览 | | | | | | | --- | --- | --- | --- | --- | --- | | 年结12月31日 | 2023 | 2024 | 2025E | 2026E | 2027E | | 收入 (百万人民币) | 126 | 707 | 1,689 | 2,819 | 3,908 | | 同比增长 (%) | 884.5 | 461.2 | 138.9 | 66.9 | 38.6 | | 净利润 (百万人民币) | (844) | (1,041) | (264) | 311 | 794 | | 每股盈利 (人民币) | (2.80) | (3.24) | (0.81) | 0.96 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][32] Core Views - The company is expected to achieve significant revenue growth in 2024, with projected revenue of CNY 240.19 billion, representing a year-on-year increase of 34% [9][11] - The net profit attributable to shareholders for 2024 is forecasted to be CNY 16.63 billion, a substantial increase of 213.32% compared to the previous year [11][9] - The company is focusing on a strategic shift towards AI and intelligent driving technologies, with the launch of the "Qianli Haohan" system aimed at enhancing its product offerings [24][26] Financial Performance - In 2024, the company achieved total sales of 2.177 million vehicles, a 32% increase year-on-year, with 41% of sales coming from new energy vehicles [2][16] - The gross margin for 2024 is reported at 15.9%, with a period expense ratio of 11.91% [13][11] - The company’s revenue from complete vehicle sales reached CNY 203.06 billion, reflecting a 36% year-on-year growth [16][2] Future Projections - For 2025, the company aims for a sales target of 2.71 million vehicles, including 1.5 million new energy vehicles [3][22] - The projected revenue for 2025 is CNY 309.74 billion, with a net profit forecast of CNY 13.7 billion [34][4] - The company plans to launch multiple new models across its brands, including the Galaxy, Zeekr, and Lynk & Co, enhancing its market presence [22][3] Valuation Metrics - The estimated earnings per share (EPS) for 2025 is projected to be CNY 1.36, with a price-to-earnings (P/E) ratio of 14-16 times [34][4] - The company’s reasonable valuation range is set between HKD 20.43 and HKD 23.34, indicating a potential upside from the current share price [6][34] - The company’s net asset return (ROE) is expected to be 13.6% in 2025, reflecting strong profitability [5][34]

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 35.82 HKD compared to the current price of 22.55 HKD [4][7]. Core Insights - The company achieved total revenue of 630 million USD in 2024, a decrease of 24% year-on-year, with oncology product revenue increasing by 67% to 271.5 million USD [2][4]. - The overseas sales of Furuzakl® have significantly increased, with a 1450% rise in revenue to 110.8 million USD, while sales in China grew by 6% to 86.3 million USD [7]. - The company has successfully expanded its commercial products into new regions and indications, with multiple approvals for Furuzakl® in various countries [7]. - The ATTC platform is set to enter clinical trials in the second half of 2025, showcasing promising early data [7]. - The company expects revenue growth in the coming years, with projected revenues of 655 million USD in 2025, 821 million USD in 2026, and 934 million USD in 2027, reflecting growth rates of 4.0%, 25.2%, and 13.8% respectively [7]. Financial Summary - The company reported a net profit of 37.7 million USD for 2024, with a cash balance of 836.1 million USD as of December 31, 2024 [2]. - The projected earnings per share (EPS) for 2025 is 0.34 CNY, with a price-to-earnings (P/E) ratio of 8.5 [4]. - The company’s total assets are expected to grow from 1.27 billion USD in 2024 to 2.06 billion USD by 2027 [8].

Investment Rating - The investment rating for Meituan-W (03690.HK) is "Outperform the Market" [6][19]. Core Views - The core business of Meituan is experiencing robust growth, with overseas expansion accelerating to support medium-term growth [1][5]. - In Q4 2024, the company reported an adjusted net profit of 9.85 billion yuan, which is in line with expectations, while revenue reached 88.49 billion yuan, reflecting a year-on-year growth of 20.1% [1][9]. - The adjusted net profit for the full year 2024 is projected to be 43.77 billion yuan, representing an 88.2% increase year-on-year, driven by improved efficiency in core operations and reduced losses in new businesses [1][9]. Summary by Sections Core Local Business - In Q4 2024, the core local business generated revenue of 65.57 billion yuan, up 18.9%, with operating profit reaching 12.90 billion yuan, a 60.9% increase [2][11]. - The operating profit margin improved to 19.7%, up 5.2 percentage points year-on-year, exceeding Bloomberg's expectations [2][11]. - The delivery service and commission revenue grew by 19.5% and 23.9% respectively, while online marketing services saw a 17.7% increase [2][11]. New Business - New business revenue in Q4 2024 was 22.92 billion yuan, a 23.5% increase, with significant growth in commission and online marketing [3][16]. - The operating loss for new businesses narrowed significantly to 2.18 billion yuan, down from 4.83 billion yuan in Q4 2023, indicating improved efficiency [3][16]. - The Meituan Youxuan segment showed notable improvement in loss reduction, while Keeta remains a primary source of increased losses due to its early-stage investment phase [3][16]. Technology and Efficiency - The company is actively integrating AI technologies to enhance employee efficiency and service upgrades, with a focus on self-developed models [4][18]. - The "Shen Huai Yuan" program has expanded to cover multiple categories, increasing cross-selling opportunities and consumer engagement [4][18]. - The gradual implementation of social security for delivery personnel is expected to increase costs but may also enhance operational efficiency in the long run [4][18]. Financial Forecasts - Revenue for 2024 is projected at 337.59 billion yuan, with a year-on-year growth of 22.0%, and adjusted net profit is expected to reach 43.77 billion yuan [8][20]. - The adjusted net profit forecast for 2025 has been slightly reduced to 51.52 billion yuan, while the 2026 forecast has been raised to 65.31 billion yuan [5][19]. - The company is expected to maintain a strong growth trajectory, supported by ongoing improvements in online penetration and expansion into new markets [5][19].

证券研究报告 泡泡玛特 (9992 HK) 港股通 新品类及全球化势能强劲，上调盈利预测 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 3 月 | 27 日│中国香港 | 消费轻工 | 公司 24 年收入 130.4 亿元，同增 106.9%；经调整净利润 34.0 亿元，同增 185.9%，高于我们预期（30.1 亿元），主因搪胶毛绒加速放量，经营杠杆释 放超预期。H2 营收同增 143.2%，经调整净利同增 264.1%。25 年指引积 极，公司凭借成熟的 IP 运营平台，推动品牌形象在全球成为时尚潮流代名 词，25 年新品类、海外扩张驱动强劲，中长期新业务持续落地，多元变现 潜力广阔。看好公司成长为全球级潮玩龙头，维持"买入"评级。 搪胶毛绒等品类创新及全球拓展势能强劲，继续成为业绩的核心驱动力 1）分品类看，H2 手办、毛绒、MEGA、衍生品增速分别达 55.5%/1362.9%/ 148.4%/454.3%，毛绒加速放量，营收占比环增 18.4pct 至 28.1%。搪胶毛 绒成为时尚单品，"包挂"风潮加速粉丝破圈，助力全年会员同增 ...

港股公司报告 | 公司点评 珍酒李渡（06979） 证券研究报告 24H2 着眼长线主动降速，25 年高质量增长可期 事件：公司发布 2024 年年报。2024 年公司收入/归母净利润/经调净利润 分别为 70.67/13.24/16.76 亿元（同比+0.5%/-43.1%/+3.3%），其中 2024H2 公司收入/归母净利润/经调净利润分别为 29.34/5.72/6.58 亿元（同比 -16.5%/-22.9%/-19.8%）。 24H2 主动去库保证渠道良性，高端聚焦主品结构阶段承压。2024H2 公司 实现营收 29.34 亿元（同比-16.46%），销量/吨价分别同比-16.79%/+0.40%。 | 投资评级 | | | --- | --- | | 行业 | 必需性消费/食物饮品 | | 6 个月评级 | 买入（维持评级） | | 当前价格 | 7.26 港元 | | 目标价格 | 港元 | 分品牌看，2024H2 珍酒/李渡/湘窖/开口笑营收分别为 17.77/6.38/3.50/1.13 亿元（同比-21.95%/+2.91%/-10.64%/-31.02%）。 分价格带看，2024H2 ...